Want to see HK:0775 full AI Analyst Report?
0775 Stock Chart & Stats
HK$0.83
>-HK$0.01(-1.22%)
At close: 4:00 PM EST
HK$0.83
>-HK$0.01(-1.22%)
Day’s Range― - ―
52-Week RangeHK$0.55 - HK$1.08
Previous CloseN/A
Volume680.00K
Average Volume (3M)7.56M
Market Cap
HK$5.38B
Enterprise ValueHK$12.46B
Total Cash (Recent Filing)HK$603.07M
Total Debt (Recent Filing)HK$6.62B
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding9,611,072,000
10 Day Avg. Volume13,068,694
30 Day Avg. Volume7,559,299
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)2.09
Price to Sales (P/S)1.46
P/FCF Ratio-28.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Agri & Environmental PortfolioA broad product set across pest management, plant health and crop enhancement, sold through a portfolio of subsidiaries in multiple markets reduces dependency on any single product or geography. This diversification supports steadier revenue streams and resiliency versus single-market players over the medium term.
In-house R&D & Biotech CapabilityOwning in-house R&D and biotech capabilities creates a durable competitive advantage by enabling proprietary products, faster iteration, and potential regulatory or IP barriers to entry. Over 2–6 months this supports product pipeline visibility and differentiation in agricultural solutions markets.
Meaningful Equity & Historical Cash GenerationA material equity base (~HK$3.8B) and multi-year history of positive operating cash flow through 2024 provide a financial cushion and tangible assets to support operations or restructuring. These features improve medium-term solvency prospects despite recent setbacks.
Bears Say
Sharp Margin CompressionA rapid decline in gross margin more than halving year-over-year signals structural pressure on pricing or rising input costs and undermines long-term profitability. Sustained margin erosion reduces capacity to fund R&D, commercial expansion, or absorb cyclical shocks without strategic change.
Negative Operating & Free Cash FlowThe reversal to negative operating cash flow and a large free-cash-flow outflow imposes durable funding stress, increasing reliance on external financing. Over several months this constrains investment, forces tighter working-capital management, and heightens refinancing and liquidity risk.
Elevated LeverageHigh and rising leverage reduces financial flexibility and raises vulnerability to earnings weakness or higher rates. Persistent debt levels near or above 1.5x equity increase interest and covenant risk, limiting capacity to invest in R&D or acquisitions and raising default risk in adverse scenarios.
CK Life Sciences International (Holdings), Inc. News
0775 FAQ
What was CK Life Sciences International (Holdings), Inc.’s price range in the past 12 months?
CK Life Sciences International (Holdings), Inc. lowest stock price was HK$0.55 and its highest was HK$1.08 in the past 12 months.
What is CK Life Sciences International (Holdings), Inc.’s market cap?
CK Life Sciences International (Holdings), Inc.’s market cap is HK$5.38B.
When is CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date?
CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 2 days.
How were CK Life Sciences International (Holdings), Inc.’s earnings last quarter?
CK Life Sciences International (Holdings), Inc. released its earnings results on Mar 17, 2026. The company reported -HK$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.004.
Is CK Life Sciences International (Holdings), Inc. overvalued?
According to Wall Street analysts CK Life Sciences International (Holdings), Inc.’s price is currently Overvalued.
Does CK Life Sciences International (Holdings), Inc. pay dividends?
CK Life Sciences International (Holdings), Inc. pays a Annually dividend of HK$0.008 which represents an annual dividend yield of N/A. See more information on CK Life Sciences International (Holdings), Inc. dividends here
What is CK Life Sciences International (Holdings), Inc.’s EPS estimate?
CK Life Sciences International (Holdings), Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CK Life Sciences International (Holdings), Inc. have?
CK Life Sciences International (Holdings), Inc. has 9,611,072,000 shares outstanding.
What happened to CK Life Sciences International (Holdings), Inc.’s price movement after its last earnings report?
CK Life Sciences International (Holdings), Inc. reported an EPS of -HK$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CK Life Sciences International (Holdings), Inc.?
Currently, no hedge funds are holding shares in HK:0775
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CK Life Sciences International (Holdings), Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.71%
Trailing 12-Months
Company Description
CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceuticals and agriculture related business. It operates through the following segments: Agriculture-Related and Health. The company was founded on August 10, 2001 and is headquartered in Hong Kong.
CK Life Sciences International (Holdings), Inc. (0775) Earnings & Revenues
Technical Analysis
Sino Biopharmaceutical
―
Ascletis Pharma, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―